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Abstract
Background: Platinum-based neoadjuvant chemotherapy (NAC) is new therapeutic strategy for
locally advanced cervical carcinoma, but the variables used to predict NAC response are still
infrequently reported. The aim of our study was to investigate the association between XRCC1
gene single nucleotide polymorphisms (SNPs) and NAC response.
Methods: Seventy patients with locally advanced cervical carcinoma who underwent NAC were
collected. SNPs of XRCC1 (at codon 194 and 399) and XRCC1 protein expression were detected.
The association of XRCC1 gene SNPs and protein expression with NAC response were analyzed.
Results: Response to NAC was not statistically significant in three genotypes, Arg/Arg, Arg/Trp,
Trp/Trp of XRCC1 at codon 194(X2 = 1.243, P = 0.07), while responses were significantly different
in genotypes Arg/Arg, Arg/Gln, Gln/Gln of XRCC1 at codon 399 (X2 = 2.283, P = 0.020). The risk
of failure to chemotherapy in the patients with a Gln allele(Arg/Gln+Gln/Gln) was significantly
greater than that with Arg/Arg(OR = 3.254, 95%CI 1.708 ~ 14.951). The expression level of
XRCC1 protein was significantly associated with response to NAC. Moreover, the genotype with
the Gln allele(Arg/Gln+Gln/Gln) at codon 399, but not codon at 194, presented a significantly
higher level of XRCC1 protein expression than that with Arg/Arg genotype (F = 2.699, p = 0.009).
Conclusion: SNP of XRCC1 gene at codon 399 influences the response of cervical carcinoma to
platinum-based NAC. This is probably due to changes in expression of XRCC1 protein, affecting
response to chemotherapy.
Background
Cervical carcinoma is the second most common malig-
nancy, and continues to be a leading cause of cancer death
in women. It is generally accepted that radical surgery or
radiotherapy can be curative for the majority of patients
with early-stage cervical carcinoma. However, the progno-
sis of locally advanced or bulky disease remains very poor,
and the optimal management for those patients is still a
matter of debate, new therapeutic strategies, such as neo-
adjuvant chemotherapy (NAC) and concurrent chemora-
diation, have been adopted to improve the prognosis for
those patients [1].
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effective for patients with locally advanced cervical carci-
noma, the use of NAC followed by radical surgery and/or
radiation for the treatment of cervical carcinoma has been
investigated extensively in the past decade, it has been
reported that NAC with cisplatinum-based chemothera-
peutic regimens have high response rates (ranging from
53% to 94%) [1,2]. However, those who have a poor
response to chemotherapy usually fail to respond to radi-
otherapy, and have a poor prognosis. Thus, NAC may
delay definitive treatment, increase cost, and result in
poorer outcomes in those patients [3]. It is important to
select appropriate patients before undergoing NAC; how-
ever, the variables used to predict NAC response are infre-
quently reported in locally advanced cervical carcinoma.
Cisplatin is considered to be the most effective drug for
the treatment of cervical carcinoma, and usually is an
essential element in the NAC regimen, but the mecha-
nisms dictating variable response to chemotherapy
among individuals are still unknown. Because platinum
compounds produce adducts and breaks in the DNA dou-
ble helix, individual variability of DNA repair may be rel-
evant in modulating the efficacy of such cytotoxic agents.
In resent years, some studies have shown that the molec-
ular condition of DNA repair genes can predict the
response of chemotherapy in some human cancers [4].
The presence of single-nucleotide polymorphisms (SNPs)
among patients suggests that genetic variability may con-
tribute to variations in responsiveness to chemotherapy
[5].
X-ray repair cross-complementing gene 1 (XRCC1) is one
of the most important DNA repair genes. The XRCC1 pro-
tein physically interacts with ligase III and poly(ADP-
robose) polymerase, acting as a scaffold in the removal of
adducts through both single-strand break repair and base
excision repair (BER), and in the repair of other types of
cisplatin-induced damage, including double-strand
breaks, through a nonhomologous end-joining pathway
[6]. There are three main coding polymorphisms in the
XRCC1 gene: at codon 194 (Arg to Trp), 280 (Arg to His),
and 399 (Arg to Gln). It was suggested that SNPs in the
XRCC1 gene may alter the ability of XRCC1 to repair dam-
aged DNA, especially SNPs at codon 399 [7]. Some studies
have shown that genetic polymorphisms of the XRCC1
gene are associated with response to platinum-based
chemotherapy in non-small-cell lung cancer, colorectal
cancer, and breast cancer [8,9], but few studies have inves-
tigated the association of XRCC1 SNPs with response to
chemotherapy in locally advanced cervical carcinoma.
Only one study has analyzed XRCC1 SNPs at codon 399,
and another study has analyzed SNPs at codon 194
recently, the results have shown that the XRCC1
Arg399Trp polymorphism or the XRCC1 Arg194Trp poly-
morphism is associated with the response to platinum-
based NAC in cervical cancer, but the number of cases
were all small (36 patients and 66 patients respectively)
[10,11]. No results of this two SNPs in the same patients
were showed.
To clarify the influence of the XRCC1 gene polymor-
phisms on the response to NAC, in the present study, we
examined the association of the different genotypes (at
codons 194 and 399), as well as protein expression with




From June 2003 to June 2007, a total of 109 patients with
histologically confirmed locally advanced cervical carci-
noma (FIGO stage IB2-IIA at least 4 cm in diameter)
underwent NAC and subsequent radical hysterectomy in
Women's Hospital School of Medicine, Zhejiang Univer-
sity. Of those, 70 patients who had complete clinical data,
peripheral blood samples, and cervical carcinoma tissures
by biopsy just before chemotherapy were enrolled in the
study. Each patient signed a form to indicate informed
consent before chemotherapy.
Chemotherapy
NAC regimens consisted of cisplatinum-based combined
chemotherapy. The regimens included BVP (blemycin 15
mg/m2, on d1, d7; cisplatin 60 mg/m2 on d1; vindesine 4
mg/m2 on d1–d2) in 47 patients, BIP (blemycin 15 mg/
m2 on d1; ifosfamide 1 g/m2 on d1–d5; cisplatin 50 mg/
m2 on d1) in 15 patients, TP (taxol 60 mg/m2 d1; cisplatin
60 mg/m2 on d1) in 8 patients. NAC was administered
every 3 to 4 weeks, for one to three cycles: one cycle in 15
patients, two cycles in 49 patients, and three cycles in 6
patients. All of the chemotherapeutic agents were admin-
istered intravenously.
Evaluation of chemotherapy response
The chemotherapy response was evaluated two weeks
after completion of the final cycle according to WHO cri-
teria, if no obvious response occurred after two cycles, the
patient would not accept another cycle of chemotherapy.
Tumor size was measured by pelvic examination and col-
poscopy as the product of the maximal perpendicular
diameter of the tumor. complete response (CR) indicates
disappearance of the disease, partial response (PR) indi-
cates at least 50% reduction in tumor load, stable disease
(SD) indicates that the lesion showed £ 25% progression
or <50% shrinkage, and progression of disease (PD) indi-
cates >25% enlargement of the lesion, or appearance of a
new lesion. CR and PR were considered to be a good
response; SD and PD, a poor response.Page 2 of 6
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Genomic DNA was extracted from peripheral blood lym-
phocytes by the routine phenol/chloroform method.
First, white blood cells were separated from red blood
cells by washing three times in phosphate buffer solution.
Then, the DNA was extracted with phenol/chloroform
and was precipitated with cold ethanol. All DNA samples
were dissolved in water and stored at -20°C.
Genotyping
The two SNPs were detected using modified polymerase
chain reaction (PCR) mismatch amplification (MA-PCR).
The two forward primers for XRCC1 gene Arg194Trp site
were 5'-GGGGGCTCTCTTCTTCAGGC-3' and 5'-GGG
GGCTCTCTTCTTCAGGT-3', which differ in the last base;
the reverse primer was 5'-CGCTGGCTGTGACTATGAAG-
3', which together produce a 362 bp fragment. The two
forward primers for the XRCC1 gene Arg399Gln site were
5'-CGTCGGCGGCTGCCCTCCTG-3' and 5'-CGTCGGCG-
GCTGCCCTCCTA-3'; the reverse primer was 5'-TTACAG-
GCGTGAGCCACTGC-3', which together produce a 354
bp fragment. For assessing the reproducibility of results,
all samples were tested twice by different technical per-
sonnel and the results were concordant for all masked
duplicate sets.
Detection of protein expression
Primary Antibodies
The rabbit anti-human polyclonal antibodies specific for
XRCC1 were purchased from Santa Cruz Biotechnology™,
Inc, Santa Cruz, California, USA.
Immunohistochemistry and Evaluation
XRCC1 protein expression was detected by Immunohisto-
chemistry, using the EnVision two-step method. The cer-
vical carcinoma samples from patients were obtained
from the paraffin-embedded tissue blocks from cervical
biopsy before therapy.
The quantitative immunoreactive scores (H-Score
method) were used to evaluate the results, calculated by
Sp(i+1), with i representing the various levels of stain: 0,
no detectable stain in the nucleus or cytoplasm; 1, yellow-
ish stain; 2, yellow stain; 3, brown stain; p represented the
percentage of samples of each stain level. Five random
fields (400× objective) were counted, and slides were
reviewed independently by two pathologists without
knowledge of the clinical data, The average of the the
quantitative immunohistochemical scores data was calcu-
lated as the final result for each sample.
Statistical analysis
Difference in frequencies of the XRCC1 genotypes and
alleles between the different chemotherapy response
groups were evaluated by X2 test and Fisher's test. The
association between XRCC1 polymorphisms and protein
expression were evaluated by variance analysis. We also
evaluated the observed genotype frequencies with those
calculated from the Hardy-Weinberg equilibrium equa-
tion (p2+2pq+q2 = 1, where p is the frequency of the vari-
ant allele and q = 1-p). We applied logistic regression to
calculate odds ratios (ORs) and 95% confidence intervals
(95% CI) for the association between the genotypes and
the risk of chemotherapy failure(SD or PD). The variance
analysis was used for measurement data. All P-values were
two-tailed and values < 0.05 were considered statistically
significant. Statistical package for social science software
(Version 11.5, SPSS Inc, Chicago, IL) was used to perform
all of the statistical analysis.
Results
Response of NAC
In the total of 70 patients, NAC response was as follows:
CR in 2 patients, PR in 58 patients, and SD in 10 patients.
No PD was found. Accordingly, the good response rate
was 85.71%; the poor response rate was 14.39%.
XRCC1 allele and genotype frequencies
The allele frequencies of XRCC1 194Arg(C) and
194Trp(T) were 65.8% and 34.2%, respectively in all
patients; the allele frequencies of XRCC1 399Arg (G) and
399Gln (A) were 80.1% and 19.9%, respectively. The dis-
tributions of these genotype frequencies were all in agree-
ment with those expected from the Hardy-Weinberg
equilibrium model, the Hardy-Weinberg equilibrium test
showed X2 = 0.03 and X2 = 1.62 respectively.
The association between XRCC1 polymorphisms and 
response to NAC
Results are shown in Table 1 for the analysis of NAC
response of patients with different genotypes. The NAC
good response rate (CR+PR) among patients with locally
advanced cervical carcinoma who carry three different
homozygous genotypes at codon 194 [Arg/Arg (CC), Arg/
Trp (CT), and Trp/Trp(TT)] were 82.35%, 100%, and
66.7% respectively. No statistically significant differences
were found among polymorphisms of XRCC1 at codon
194 (X2 = 1.243, P = 0.07).
XRCC1 gene polymorphisms at codon 399 were found to
be significantly associated with NAC response. The NAC
response rate (CR+PR) among patients with locally
advanced cervical carcinoma carrying three different
homozygous genotypes at codon 399 [Arg/Arg (GG), Arg/
Gln (GA), and Gln/Gln(AA)] were 90.0%, 0% (0/2), and
83.33%, respectively (X2 = 2.283, P = 0.02). Logistic
regression analysis showed a significantly increased rate of
failure of NAC in patients with at least one Gln allele [Arg/
Gln(GA)+Gln/Gln(AA)] versus the Arg/Arg (GG) geno-
type (odds ratio 3.254; 95% CI 1.708–14.951; P = 0.002).Page 3 of 6
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The level of XRCC1 protein expression was significantly
higher in patients with poor response to NAC (SD+PD)
than it was in those with good response (CR+PR) (2.99 ±
0.38 vs. 1.94 ± 0.28; t = 13.64, P = 0.008).
The association between XRCC1 polymorphisms and 
protein expression
The association of the variant genotypes at codon 194 and
399 with expression of the XRCC1 protein in locally
advanced cervical carcinoma tissues were further evalu-
ated, as shown in Table 2. No statistically significant dif-
ference was found between the codon 194 polymorphism
and XRCC1 protein expression(F = 1.186, P = 0.103);
however, there was a statistically significant association
between codon 399 polymorphism and XRCC1 protein
expression (F = 15.915, P < 0.001).
In addition, the level of expression of XRCC1 protein in
patients with at least one Gln allele [Arg/Gln (GA) + Gln/
Gln (AA)] was significantly higher than that in the
patients with the Arg/Arg (GG) genotype (F = 2.699, P =
0.009).
Discussion
It is well known that DNA repair is very important in the
maintenance of genetic stability, and in protection against
the initiation of cancer. Owing to its possible effects on
gene expression, polymorphisms of DNA repair genes
related to metabolism may influence tumor response to
chemotherapy or radiotherapy. The identification of
molecular variables that predict either sensitivity or resist-
ance to chemotherapy is of major interest in selecting the
first-line treatment most likely to be effective. Because
XRCC1 is one of the most important DNA repair genes,
the main aim of the present study was to determine
whether the XRCC1 genetic polymorphisms could predict
clinical response of patients with locally advanced cervical
carcinoma to platinum-based NAC.
Some studies have assessed the association between
XRCC1 gene polymorphisms and chemotherapy response
in various carcinomas, but the results are inconsistent.
There has been increasing evidence that decreased DNA
repair capacity resulting from genetic polymorphisms of
various DNA repair genes is associated with improved sur-
vival of cancer patients treated with platinum-based
chemotherapy, especially in non-small cell lung cancer
[12]. Studies addressing the association of XRCC1 gene
polymorphisms at codon 194 with chemotherapy
response have focused mainly on non-small cell lung can-
cer. Wang and his colleagues reported 105 patients with
non-small lung cancer undergoing platinum-based chem-
otherapy, and found that the response rate was signifi-
cantly higher in patients carrying at least one Trp allele
than in those with the Arg/Arg genotype (43.1% vs.
20.3%) [13]. In patients with advanced-stage lung cancer,
the risk of failure of chemotherapy was five-fold higher in
patients with Arg/Arg genotype at codon 194 than in
Table 1: The association between XRCC1 polymorphisms at codons 194 and 399 and NAC response in locally advanced cervical 
carcinoma







34 28 (82.35) 6 (17.65)
Arg/Trp 24 24 (100) 0 (0)
Trp/Trp 12 8 (66.67) 4 (33.33) 2.333 0.52~10.35
Arg/Trp+ Trp/Trp 36 32 (88.89) 4 (11.11) 0.583* 0.14~2.28
Codon 399
Arg/Arg
44 40(90.90) 4 (9.10)
Arg/Gln 2 0 (0) 2 (100)
Gln/Gln 24 20 (83.33) 4 (16.67) 2.000 0.452 ~8.842
Arg/Gln+ Gln/Gln 26 20 (76.92) 6 (23.08) 3.254** 1.708 ~ 14.951
Good response: CR+PR; Poor response: SD+PD; OR: odds ratio
*: Arg/Trp+Trp/Trp vs Arg/Arg; **: Arg/Gln+Gln/Gln vs Arg/Arg
Table 2: The association between XRCC1 polymorphisms and 
protein expression in locally advanced cervical carcinoma
XRCC1 genotype N X ± SD F P
Codon 194
Arg/Arg 34 2.306 ± 0.658
Arg/Trp 24 1.813 ± 0.341 1.186 0.103
Trp/Trp 12 2.217 ± 0.446
Codon 399
Arg/Arg 44 1.986 ± 0.404
Arg/Gln 24 2.224 ± 0.604 15.915 <0.001
Gln/Gln 2 3.890 ± 0.000
Arg/Gln
+ Gln/Gln
26 2.352 ± 0.735 2.699 * 0.009
*: Arg/Gln+Gln/Gln vs Arg/ArgPage 4 of 6
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some other studies did not find that the SNPs of XRCC1
contributed to susceptibility to cancer or to sensitivity to
chemotherapy. These inconsistent results may be related
to the different types of cancers studied in different ethnic
populations [15,16].
Only one study assessed the association between XRCC1
gene polymorphisms at codon 194 and NAC response in
cervical cancer, recently, Kim and his colleagues reported
66 patients with cervical cancer undergoing platinum-
based NAC, the results showed that the genotypes of
XRCC1 Arg194Trp was associated with the response [11].
But Our current report did not find any significant associ-
ation, the inconsistent results may be related to the differ-
ent ethnic populations and the limitatiom of the sample.
It has been suggested that the SNPs of XRCC1 at codon
399 may influence the outcome of cisplatinum-based
chemotherapy in some human carcinomas, but the results
are also variable. Wang and his colleagues reported that in
patients with non-small cell lung cancer who received the
platinum-based chemotherapy, the response rate was sig-
nificantly higher in patients with the Arg/Arg genotype
than that in those with at least one Gln allele (41.5% vs.
21.2%). In contrast, other studies of patients with neck
cancer revealed that sensitivity to chemotherapy was
higher in patients with a Gln allele than in those with
other genotypes [13,17]. Moreno and colleagues also
found that the prognosis of colorectal cancer patients
receiving chemotherapy with 5-FU was better in patients
with the 399Gln/Gln genotype than in those with Arg/Arg
or Arg/Gln genotype [18]. While in a recent study, no sig-
nificant association was found between the SNPs of
XRCC1 at codon 399 and the response to chemotherapy
in non-small cell lung cancer [14].
Our study showed that the response to chemotherapy in
locally advanced cervical carcinoma was significantly
higher in patients with the Arg/Arg genotype at codon 399
than in those with the Arg/Gln or Gln/Gln genotype
(90.0% vs. 76.92%). The risk of failure of NAC therapy
was 3.254 fold higher in patients carrying at least one Gln
allele compared with those carrying no Gln allele. Our
findings suggest that SNPs of the XRCC1 gene at codon
399 influences the response of cervical carcinoma to plat-
inum-based neoadjuvant chemotherapy, and that the
genotype carrying at least one Gln allele may be consid-
ered to be a candidate molecular marker to predict poor
response to NAC in locally advanced cervical carcinoma.
The fact that SNPs of XRCC1 at codon 399 influences
response to NAC in locally advanced cervical carcinoma
affirms previous results reported by the studies of other
carcinomas, but the exact mechanism remains unknown
[13,17,19]. Some studies have shown that resistance to
platinum-based agents was related to the overexpression
of DNA-repair protein [20]. Dabholkar and colleagues
found that the mRNA level of some DNA repair gene was
significantly increased in platinum-resistant ovarian carci-
noma, indicating that the level of DNA repair gene expres-
sion correlates with the response to platinum-based
chemotherapy [21].
Similarly, our results also showed that the level of XRCC1
protein expression was significantly higher in patients
with poor response than in those with good response to
NAC in locally advanced cervical carcinoma. In addition,
we found that this altered expression of the XRCC1 pro-
tein was associated with XRCC1 genotype variation at
codon 399, the protein expression was significantly
higher in the patients with a Gln allele (Arg/Gln or Gln/
Gln) than that with the Arg/Arg genotype in locally
advanced cervical carcinoma. Our findings suggest that
the genotype with at least one Gln allele probably
increases the expression of XRCC1 protein, and conse-
quently, results in poor response to platinum-based
chemotherapy in patients with locally advanced cervical
carcinoma. To our knowledge, this is the first investiga-
tion of XRCC1 gene SNPs, protein expression, and their
association with response to chemotherapy. Further study
is needed to clarify the mechanism behind this phenome-
non.
We have demonstrated that SNPs of the XRCC1 gene at
codon 399 influence the response of patients with locally
advanced cervical carcinoma to platinum-based NAC.
Patients with a genotype carrying at least one Gln allele
have an increased risk of failure to respond to chemother-
apy compared with those carrying no Gln allele. This
reduced response to chemotherapy is probably due to ele-
vated expression of XRCC1 protein in those patients who
have at least one Gln allele.
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